Episode Details

Harrow enters a deal to expand it biosimilar pharma portfolio; the first gene-agnostic therapy to restore vision in RP patients advances; and Aldeyra provides an update on its dry eye drug candidate reproxalap.

Learn more about your ad choices. Visit megaphone.fm/adchoices